- Case-Based Modules
- Initial Evaluation
- Dermatologic Manifestations
- Oral Manifestations
- OIs: Prophylaxis
- OIs: Treatment
- Antiretroviral Rx
- Antiretroviral Rx: Resistance
- Antiretroviral Rx: Adverse Effects
- Drug-Drug Interactions
- Postexposure Prophylaxis
- Perinatal Transmission
- Special Populations
- Prevention for Positives
- Challenging Unknowns
- Resource-Limited Settings
- Interactive Tutorials
- Routine HIV Screening
- Oraquick Advance Rapid HIV Test
- HIV Integration
- This program is funded through Health Resources and Services Administration, US Department of Health and Human Services.
Drug-Drug Interactions
Question | Discussion | References | CME Credit
Updated July 6, 2012
Case 4: Antiretrovirals and Oral Contraceptives
| Author: | Bradley W. Kosel, PharmD David H. Spach, MD |
- Describe the predicted impact of non-nucleoside reverse transcriptase inhibitors(NNRTIs) on the efficacy of oral contraceptives.
- Understand key interactions between protease inhibitors (PIs) and oral contraceptives.
A 25-year-old female with a CD4 cell count of 168 cells/mm3 presents to clinic to 3 months after having a new diagnosis of HIV. Three weeks ago she was started on trimethoprim-sulfamethoxazole (Bactrim, Septra) and she is tolerating this well. She takes norethindrone/ethinyl estradiol (Ortho Novum 7/7/7 Triphasic) for birth control and admits that her boyfriend is unlikely to consistently use condoms. You are planning to start her on antiretroviral therapy, but are concerned about how the antiretroviral medications may interact with her birth control pills.
Which of the following is TRUE regarding a potential drug-drug interactions with antiretroviral medications and the oral contraceptive?
Copyright © 2004-2013 University of Washington